ASCO Guidance, FDA Approves Rubraca, Nivolumab vs. BevacizumabMay 25, 2020 | Oncology Internal Medicine ASCO Offers Guidance on Resuming Cancer Care During COVID-19 In this Special Report, the American Society of Clinical Oncology (ASCO) publishes guidance for oncology practices on how to safely restore patient access to diagnostics, treatments, and other critical cancer care services. Read full article Hematology FDA Approves Rubraca, First PARP Inhibitor for Prostate Cancer Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians. Read full article Hematology Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma In this Original Investigation, JAMA Oncology explores the CheckMate 143 Phase 3 trial, asking whether PD-1 immune checkpoint inhibition with nivolumab improves overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS